医薬品研究
Pharm. Regul. Sci.
39(12)807～808(2008)

フォーラムの成果**
—学から—

畠　清彦*

Achievements of the Forum for Anticancer Drug Development from an Academic Perspective**

Kiyohiko HATAKE*

Summary

So far, the Forum for Anticancer Drug Development has met four times and various factors related to delays in approval of new drugs were discussed. We evaluated the efficacy of this forum to see whether or not it should be continued. Preclinical studies, before phase I clinical trial, are efficient in Japan, but the number of sites available for phase I clinical trials is too small. It is important to reduce delays in obtaining approval for new drugs, and practical action is still needed.

1. The PMDA is trying to increase the number of staff involved in the approval procedures.
2. The JSMO and academia are trying to increase the numbers of medical oncologists and to expand departments of medical oncology in medical schools.
3. Postmarketting surveillance should be simplified or should be omitted.
4. It is considered that the Forum is useful in promoting communication among people involved in the approval of new drugs, including PMDA, academia, and pharmaceutical companies.

Key words

Postmarketing surveillance, Drug approval, Medical oncologist, Evaluation of forum